FDA bile duct if successful should lead to a rerate. So would TGA approval.
Both strategies were covered in the latest business update plus the conference call.
Plus, still have the private payer market, especially in London.
Plus as TT mentioned they may still be able to do some clinical studies in the UK and Germany as mentioned in the business update to support public reimbursement.
FDA bile duct if successful should lead to a rerate. So would...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(4.76%) |
Mkt cap ! $41.62M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $36.16K | 3.384M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 14154999 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 5667943 | 6 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |